{"id":26670,"date":"2025-04-17T05:14:09","date_gmt":"2025-04-17T05:14:09","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/26670\/"},"modified":"2025-04-17T05:14:09","modified_gmt":"2025-04-17T05:14:09","slug":"ozempic-linked-to-lower-alzheimers-risk","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/26670\/","title":{"rendered":"Ozempic Linked to Lower Alzheimer\u2019s Risk"},"content":{"rendered":"<p><strong>Summary: <\/strong>A new study suggests that two widely used Type 2 diabetes medications\u2014GLP-1 receptor agonists and SGLT2 inhibitors\u2014may help reduce the risk of Alzheimer\u2019s disease and related dementias. Researchers analyzed Medicare data and found that patients taking these drugs had significantly lower rates of cognitive decline compared to those using other glucose-lowering medications.<\/p>\n<p>The findings point to potential neuroprotective effects, even for individuals without diabetes. Scientists plan to explore the broader implications of these medications as preventative or therapeutic options for Alzheimer\u2019s in larger and more diverse populations.<\/p>\n<p><strong>Key Facts:<\/strong><\/p>\n<ul class=\"wp-block-list\">\n<li><strong>Protective Link:<\/strong> GLP-1RAs and SGLT2is were associated with reduced Alzheimer\u2019s risk.<\/li>\n<li><strong>Neuroprotective Potential:<\/strong> These drugs may benefit brain health beyond diabetes control.<\/li>\n<li><strong>Future Research:<\/strong> Studies will explore their effects in non-diabetic populations.<\/li>\n<\/ul>\n<p><strong>Source: <\/strong>University of Florida<\/p>\n<p><strong>A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of Alzheimer\u2019s disease and related dementias in patients with Type 2 diabetes.<\/strong><\/p>\n<p>In research published in\u00a0JAMA Neurology\u00a0on April 7, UF researchers studied Medicare claims data of older adults with Type 2 diabetes to assess the association among glucagon-like peptide-1 receptor agonists, or GLP-1RAs, sodium-glucose cotransporter-2 inhibitors, or SGLT2is, and the risk of Alzheimer\u2019s disease and related dementias.<\/p>\n<p>  <img fetchpriority=\"high\" decoding=\"async\" width=\"1200\" height=\"799\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/04\/ozempic-Alzheimers-neuroscience.jpg\" alt=\"This shows two women and a brain.\"  \/> The data showed a statistically significant association between a lower risk of Alzheimer\u2019s and the use of GLP-1RAs and SGLT2is compared with other glucose-lowering medications. Credit: Neuroscience News<\/p>\n<p>The research is supported by funding from the National Institute on Aging and the National Institute of Diabetes and Digestive and Kidney Diseases, both part of the National Institutes of Health.<\/p>\n<p>The data showed a statistically significant association between a lower risk of Alzheimer\u2019s and the use of GLP-1RAs and SGLT2is compared with other glucose-lowering medications.<\/p>\n<p>According to the researchers, the findings indicated that the two drugs may have neuroprotective effects for people without diabetes and may help slow the rate of cognitive decline in Alzheimer\u2019s patients.<\/p>\n<p>Serena Jingchuan Guo, M.D., Ph.D., an assistant professor of pharmaceutical outcomes and policy and the study\u2019s senior author, said these findings may point to new therapeutic uses for drugs commonly used to treat Type 2 diabetes and obesity.<\/p>\n<p>\u201cIt\u2019s exciting that these diabetes medications may offer additional benefits, such as protecting brain health,\u201d Guo said.<\/p>\n<p>\u201cBased on our research, there is promising potential for GLP-1RAs and SGLT2is to be considered for Alzheimer\u2019s disease prevention in the future. As use of these drugs continues to expand, it becomes increasingly important to understand their real-world benefits and risks across populations.\u201d<\/p>\n<p>Guo conducted this research in collaboration with\u00a0William Donahoo, M.D., clinical professor and chief of the UF Health Division of Endocrinology, Diabetes and Metabolism, and\u00a0Steven T DeKosky, M.D., deputy director of the McKnight Brain Institute and professor of Alzheimer\u2019s research, neurology and neuroscience in the UF Department of Neurology.<\/p>\n<p>As the study only included patients with Type 2 diabetes, Guo said next steps include evaluating the effects of the two drugs in broader populations by using recent, real-world data that captures their growing use in clinical settings.<\/p>\n<p>\u201cFuture research should focus on identifying heterogeneous treatment effects \u2014 specifically, determining which patients are most likely to benefit and who may be at greater risk for safety concerns,\u201d Guo said.<\/p>\n<p>About this neuropharmacology and Alzheimer\u2019s disease research news<\/p>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Author: <\/strong><a href=\"http:\/\/neurosciencenews.com\/cdn-cgi\/l\/email-protection#d7b2a5beb4f9bfb6babebba3b8b997a2b1bbf9b2b3a2\" target=\"_blank\" rel=\"noreferrer noopener\">Eric Hamilton<\/a><br \/><strong>Source: <\/strong><a href=\"https:\/\/ufl.edu\" target=\"_blank\" rel=\"noreferrer noopener\">University of Florida<\/a><br \/><strong>Contact: <\/strong>Eric Hamilton \u2013 University of Florida<br \/><strong>Image: <\/strong>The image is credited to Neuroscience News<\/p>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Original Research: <\/strong>Closed access.<br \/>\u201c<a href=\"https:\/\/dx.doi.org\/10.1001\/jamaneurol.2025.0353\" target=\"_blank\" rel=\"noreferrer noopener\">GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias<\/a>\u201d by Serena Jingchuan Guo et al. JAMA Neurology<\/p>\n<p><strong>Abstract<\/strong><\/p>\n<p><strong>GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias<\/strong><\/p>\n<p><strong>Importance<\/strong>\u00a0\u00a0<\/p>\n<p>The association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) and risk of Alzheimer disease and related dementias (ADRD) remains to be confirmed.<\/p>\n<p><strong>Objective<\/strong>\u00a0\u00a0<\/p>\n<p>To assess the risk of ADRD associated with GLP-1RAs and SGLT2is in people with type 2 diabetes (T2D).<\/p>\n<p><strong>Design, Setting, and Participants<\/strong>\u00a0\u00a0<\/p>\n<p>This target trial emulation study used electronic health record data from OneFlorida+ Clinical Research Consortium from January 2014 to June 2023. Patients were 50 years or older with T2D and no prior diagnosis of ADRD or antidementia treatment. Among the 396\u202f963 eligible patients with T2D, 33\u202f858 were included in the GLP-1RA vs other glucose-lowering drug (GLD) cohort, 34\u202f185 in the SGLT2i vs other GLD cohort, and 24\u202f117 in the GLP-1RA vs SGLT2i cohort.<\/p>\n<p><strong>Exposures<\/strong>\u00a0\u00a0<\/p>\n<p>Initiation of treatment with a GLP-1RA, SGLT2i, or other second-line GLD.<\/p>\n<p><strong>Main Outcomes and Measures<\/strong>\u00a0\u00a0<\/p>\n<p>ADRD was identified using clinical diagnosis codes. Hazard ratios (HRs) with 95% CIs were estimated using Cox proportional hazard regression models with inverse probability of treatment weighting (IPTW) to adjust for potential confounders.<\/p>\n<p><strong>Results<\/strong>\u00a0\u00a0<\/p>\n<p>This study included 33\u202f858 patients in the GLP-1RA vs other GLD cohort (mean age, 65 years; 53.1% female), 34\u202f185 patients in the SGLT2i vs other GLD cohort (mean age, 65.8 years; 49.3% female), and 24\u202f117 patients in the GLP-1RA vs SGLT2i cohort (mean age, 63.8 years; 51.7% female). In IPTW-weighted cohorts, the incidence rate of ADRD was lower in GLP-1RA initiators compared with other GLD initiators (rate difference [RD], \u22122.26 per 1000 person-years [95% CI, \u22122.88 to \u22121.64]), yielding an HR of 0.67 (95% CI, 0.47-0.96). SGLT2i initiators had a lower incidence than other GLD initiators (RD, \u22123.05 per 1000 person-years [95% CI, \u22123.68 to \u22122.42]), yielding an HR of 0.57 (95% CI, 0.43-0.75). There was no difference between GLP-1RAs and SGLT2is, with an RD of \u22120.09 per 1000 person-years (95% CI, \u22120.80 to 0.63) and an HR of 0.97 (95% CI, 0.72-1.32).<\/p>\n<p><strong>Conclusion and Relevance<\/strong>\u00a0\u00a0<\/p>\n<p>In people with T2D, both GLP-1RAs and SGLT2is were statistically significantly associated with decreased risk of ADRD compared with other GLDs, and no difference was observed between both drugs.<\/p>\n","protected":false},"excerpt":{"rendered":"Summary: A new study suggests that two widely used Type 2 diabetes medications\u2014GLP-1 receptor agonists and SGLT2 inhibitors\u2014may&hellip;\n","protected":false},"author":2,"featured_media":26671,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[231,215,16231,105,219,233,7206,220,370,16,15,16232,10891],"class_list":{"0":"post-26670","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-alzheimers-disease","9":"tag-brain-research","10":"tag-glp-1","11":"tag-health","12":"tag-neurobiology","13":"tag-neurology","14":"tag-neuropharmacology","15":"tag-neuroscience","16":"tag-ozempic","17":"tag-uk","18":"tag-united-kingdom","19":"tag-university-of-florida","20":"tag-wegovy"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114351601691367009","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/26670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=26670"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/26670\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/26671"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=26670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=26670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=26670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}